ClinicalTrials.gg
Sign In
CompletedNCT03497000Updated Apr 17, 2018

Effects of OCTA-guided PDT in Acute CSC

An interventional study of OCTA-guided Photodynamic therapy and ICGA-guided Photodynamic therapy in Central Serous Chorioretinopathy and Tomography, Optical Coherence, sponsored by Peking University People's Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-04-17.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Sep 2017, registered Mar 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

OCTA-guided PDT is as safe and effective as ICGA-guided PDT in the treatment of acute central serous chorioretinopathy. Or OCTA-guided PDT is more effective than ICGA-guided PDT in the treatment of acute central serous chorioretinopathy, safe as well.

02

Conditions studied

  • Central Serous Chorioretinopathy
  • Tomography, Optical Coherence

Keywords

  • optical coherence tomography angiography
  • central serous chorioretinopathy
  • photodynamic therapy
03

In context

Central Serous Chorioretinopathy

84 studies on the registry are indexed under Central Serous Chorioretinopathy; 14 are open to participants now.

This study's enrollment of 23 is below the median of 35 across 60 interventional studies indexed under Central Serous Chorioretinopathy.

Browse Central Serous Chorioretinopathy studies →

Lead sponsor

Peking University People's Hospital is the lead sponsor of 609 studies on the registry; 247 are open to participants now.

Browse Peking University People's Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Idiopathic detachment of the neurosensory retina with a focal leak at the level of the RPE with FA
  • Presence of SRF and/or serous pigment epithelial detachment on OCT
  • Presence of abnormal dilated choroidal vasculature in ICGA

Exclusion criteria

Exclusion Criteria:

  • Patients with other ocular conditions commonly associated with SRF, such as choroidal neovascularization, polypoidal choroidal vasculopathy (PCV), diabetic retinopathy, retinal vascular occlusion, Coat's disease
  • Any disease that may affect the quality of imaging (quality of OCTA images \< 6), such as cataract, high myopia or nystagmus
  • History of ocular surgeries including retinal laser
  • Pregnancy
  • Any uncontrolled systemic disease
  • Any condition rendering patients intolerable to image acquisition
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    OCTA group

    Patients in this group underwent OCTA-guided half-dose photodynamic therapy.

    Procedure: OCTA-guided Photodynamic therapy

  • Active comparator
    ICGA group

    Patients in this group underwent normal ICGA-guided half dose photodynamic therapy.

    Procedure: ICGA-guided Photodynamic therapy

Interventions

  • ProcedureOCTA-guided Photodynamic therapy

    Half-dose photodynamic therapy using verteporfin under the guidance of OCTA

  • ProcedureICGA-guided Photodynamic therapy

    Half-dose photodynamic therapy using verteporfin under the guidance of ICGA

06

What researchers measure

Primary outcomes

  1. Number of patients with subretinal fluid resolution on OCT after PDT of two groups

    Time frame: 3 months

Secondary outcomes

  1. Number of patients with leakage point resolution on FFA after PDT of two groups

    Time frame: 3 months

  2. Number of recurrent CSC after PDT of two groups

    Time frame: 3 months

  3. BCVA (best corrected visual acuity) at every follow-up of two groups

    Time frame: 1 month, 3 months

07

Study locations

1 site
  • People's Hospital of Peking University
    Beijing, Beijing 100044, China
08

References and documents

Publications

  • Hu J, Qu J, Li M, Sun G, Piao Z, Liang Z, Yao Y, Sadda S, Zhao M. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2021 Jan 1;41(1):189-198. doi: 10.1097/IAE.0000000000002795. PubMed 32343102 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03497000
Lead sponsor
Peking University People's Hospital
Collaborators
National Natural Science Foundation of China
Responsible party
Mingwei Zhao (Head of Ophthalmology, Professor, Peking University People's Hospital) — Principal investigator
First posted
Apr 12, 2018
Start date
Sep 1, 2017
Primary completion
Dec 1, 2017
Completion
Mar 27, 2018
Last update
Apr 17, 2018

Study contacts

Mingwei Zhao, M.D
study director · Peking University People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Central Serous Chorioretinopathy →

Other studies from this sponsor

Peking University People's Hospital →

Start the discussion